Robert G Maki Selected Research

Antineoplastic Agents (Antineoplastics)

1/2020	Multiplexed Evaluation of Microdosed Antineoplastic Agents In Situ in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma.
10/2018	Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment.
10/2002	Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert G Maki Research Topics

Disease

86	Neoplasms (Cancer) 11/2023 - 08/2002
81	Sarcoma (Soft Tissue Sarcoma) 10/2023 - 08/2002
33	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 11/2020 - 08/2002
16	Liposarcoma 11/2020 - 10/2004
14	Disease Progression 01/2022 - 05/2005
14	Leiomyosarcoma 12/2019 - 06/2007
9	Osteosarcoma (Osteogenic Sarcoma) 11/2022 - 08/2003
9	Hemangiosarcoma (Angiosarcoma) 01/2022 - 05/2005
9	Neoplasm Metastasis (Metastasis) 01/2019 - 08/2002
8	Ewing Sarcoma (Sarcoma, Ewing) 01/2023 - 03/2007
8	Synovial Sarcoma (Synovioma) 01/2022 - 06/2007
6	Fatigue 11/2022 - 03/2012
6	Aggressive Fibromatosis (Desmoid) 01/2022 - 06/2007
5	Neurofibrosarcoma (MPNST) 01/2023 - 07/2009
5	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 07/2015 - 08/2002
5	Dermatofibrosarcoma 09/2011 - 08/2002
4	Hypertension (High Blood Pressure) 01/2022 - 02/2008
4	Rhabdomyosarcoma 01/2021 - 03/2007
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2011 - 10/2010
3	Nausea 01/2022 - 03/2012
3	Genetic Translocation (Chromosomal Translocation) 11/2012 - 08/2002
2	Lung Neoplasms (Lung Cancer) 07/2023 - 10/2010
2	Hypophosphatemia 01/2023 - 05/2006
2	Fever (Fevers) 11/2022 - 01/2019
2	Histiocytic Sarcoma 04/2022 - 11/2015
2	Diarrhea 01/2022 - 12/2018
2	Vomiting 01/2022 - 06/2012
2	Epistaxis (Nosebleed) 01/2022 - 01/2009
2	Anemia 01/2022 - 01/2017
2	Lymphoma (Lymphomas) 04/2020 - 01/2018
2	Cardiotoxicity 01/2020 - 10/2005
2	Thrombocytopenia (Thrombopenia) 01/2017 - 01/2009
2	Pigmented Villonodular Synovitis 01/2015 - 03/2012
2	Neutropenia 06/2012 - 03/2012
2	Fibroma (Fibromatosis) 06/2011 - 05/2010
2	Malignant Fibrous Histiocytoma 07/2009 - 08/2007
1	Neoplasm Micrometastasis 11/2022
1	Injection Site Reaction 11/2022
1	Myxoid Liposarcoma 01/2022
1	Headache (Headaches) 01/2022

Drug/Important Bio-Agent (IBA)

36	Imatinib Mesylate (Gleevec)FDA Link 11/2023 - 08/2002
20	Phosphotransferases (Kinase)IBA 11/2023 - 08/2007
13	Sunitinib (Sutent)FDA Link 01/2019 - 10/2006
11	Dacarbazine (DIC)FDA LinkGeneric 12/2019 - 04/2004
11	TrabectedinIBA 12/2019 - 10/2002
10	Tyrosine Kinase InhibitorsIBA 11/2022 - 04/2004
10	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 04/2004
8	AnthracyclinesIBA 04/2020 - 05/2010
7	Proteins (Proteins, Gene)FDA Link 03/2023 - 07/2003
7	regorafenibIBA 01/2023 - 01/2013
7	Sorafenib (BAY 43-9006)FDA Link 01/2022 - 08/2007
7	Ifosfamide FDA LinkGeneric 01/2017 - 04/2004
6	pazopanib FDA Link 01/2022 - 05/2015
6	Gemcitabine FDA Link 01/2020 - 04/2004
6	CrizotinibIBA 01/2020 - 10/2010
6	DNA (Deoxyribonucleic Acid)IBA 06/2019 - 01/2008
4	Immune Checkpoint InhibitorsIBA 07/2023 - 07/2016
4	eribulin FDA Link 01/2019 - 10/2011
4	Docetaxel (Taxotere)FDA Link 01/2019 - 07/2007
4	Monoclonal AntibodiesIBA 01/2019 - 11/2010
4	Sirolimus (Rapamycin)FDA Link 02/2014 - 06/2007
3	VaccinesIBA 11/2022 - 07/2006
3	AntibodiesIBA 11/2022 - 07/2003
3	AntigensIBA 04/2020 - 07/2006
3	Antineoplastic Agents (Antineoplastics)IBA 01/2020 - 10/2002
3	RNA (Ribonucleic Acid)IBA 06/2019 - 08/2003
3	Insulin-Like PeptidesIBA 01/2013 - 11/2010
3	tyrosine receptor (receptor, tyrosine)IBA 01/2011 - 02/2008
2	IpilimumabIBA 04/2020 - 01/2013
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 12/2019
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2018 - 10/2010
2	Bevacizumab (Avastin)FDA Link 01/2015 - 10/2005
2	teprotumumabIBA 08/2014 - 12/2011
2	TensinsIBA 02/2014 - 12/2012
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 02/2014 - 12/2012
2	Transcription Factors (Transcription Factor)IBA 11/2012 - 03/2012
2	Paclitaxel (Taxol)FDA LinkGeneric 07/2012 - 05/2005
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 05/2012 - 03/2005
2	Anaplastic Lymphoma KinaseIBA 05/2011 - 10/2010
2	Fluorouracil (Carac)FDA LinkGeneric 05/2009 - 03/2005
2	CollagenIBA 05/2006 - 08/2002
2	Alkaline PhosphataseIBA 05/2006 - 09/2005
1	Tyrosine (L-Tyrosine)FDA Link 01/2023
1	Programmed Cell Death 1 ReceptorIBA 01/2023
1	GangliosidesIBA 11/2022
1	Immunologic Adjuvants (Immunologic Adjuvant)IBA 11/2022
1	carotuximabIBA 01/2022
1	atezolizumabIBA 01/2022
1	Lenalidomide (CC 5013)FDA Link 01/2022
1	Vinca AlkaloidsIBA 01/2022
1	IminesIBA 01/2022

Therapy/Procedure

64	Therapeutics 07/2023 - 08/2002
39	Drug Therapy (Chemotherapy) 07/2023 - 04/2004
8	Radiotherapy 02/2021 - 03/2007
5	Neoadjuvant Therapy 10/2023 - 08/2009
5	Immunotherapy 07/2023 - 07/2006
4	Adjuvant Chemotherapy 04/2022 - 04/2004
2	Drug Tapering 01/2023 - 01/2019
2	Metastasectomy 11/2022 - 01/2022
2	Aftercare (After-Treatment) 02/2011 - 01/2008